Nilang Patel, MD, MS, FASN

Associate Professor, Nephrology @VCU @VCUHealth @RichmondVAMC - Views expressed here are my own and not of my employer's, Likes & Retweets aren't endorsements.

[Jasmohan Bajaj @JasmohanBajaj]

A🌎study of >2500 #cirrhosis inpts➡️no link b/w #rifaximin & drug-resistant #infections
Done w #CLEARED consortium
🔑#rifaximin➡️useful for #HE
✅real-world evidence before changing practice!

@CMH_journal https://t.co/BUbvyG8Wvd
builds on @AGA_Gastro https://t.co/QSMObg68R7

[Nilang Patel, MD, MS, FASN @nilangpatel]

Optimal #A1c target in #diabetic #Kidney #transplant remain unclear. @goKDIGO @AST_info has non-graded recommendation of #HgbA1c 7.0-7.5%. We noted that A1c target of 7-8% is THE SWEET SPOT. Check out our latest research. @VCU_Nephrology @VCU @RichmondVAMC

[Nilang Patel, MD, MS, FASN @nilangpatel]

Our research is being highlighted by @VAResearch @RichmondVAMC @VCU_Liver @DeptVetAffairs

[Jasmohan Bajaj @JasmohanBajaj]

thanks for highlighting our @JHEP_Reports study https://t.co/tNGE4nJXYR done in collaboration with @nilangpatel and @VCUdentistry! @DeptVetAffairs @VAResearch

[Nilang Patel, MD, MS, FASN @nilangpatel]

Poor #oral #health associated with systemic #inflammation and unfavorable outcomes. What happens if #cirrhosis patient receives regular #dental #prophylaxis and #periodontal #maintenance?
https://t.co/OxDyClupWP @VCU @VCU_Nephrology @VAResearch @JHEP_Reports

[Jasmohan Bajaj @JasmohanBajaj]

Clean🦷to prevent #livercancer? not as outlandish!
@JHEP_Reports @nilangpatel
🔑Professional #orodental care⬇️#decomp, #HCC & hospitalizations in #compensated #cirrhosis
🔑effect🚫w other screen (colon)
🔑 oral-gut-liver axis
🔑 don't wait till LT!
https://t.co/tNGE4nJXYR

[Nilang Patel, MD, MS, FASN @nilangpatel]

#Vonoprazan showed better outcome in #AKI prevention in #cirrhosis compared to #PPIs.  Reduced acute kidney injury (#AKI) likely from reduced rate of infection, sepsis, variceal bleeding, and liver-related complications and hospitalization over both six- and twelve-month periods. @VCU @VCUHealth @RichmondVAMC

https://t.co/qlmDP8HIM6

[Jasmohan Bajaj @JasmohanBajaj]

Both #PCABs & #PPI suppress acid but have different PK & #microbial impact....do they impact #cirrhosis outcomes differently? YES
In Asia-Pacific @TriNetX w many sensitivity analyses, #Vonoprazan ➡️ better outcomes vs PPI
@AmJGastro @nilangpatel et al⤵️
https://t.co/MeDhajOsdT

[Jasmohan Bajaj @JasmohanBajaj]

Can we use NLP #AI to ⬆️objectivity of #Hepaticencephalopathy diagnosis?

Yes! 3 cohorts (@RichmondVAMC @VCU_Liver #NACSELD) showed 5 phrases w ⬆️value

Implications for
🔑 #Transplant priority
🔑 remote adjudication of clinical trials

https://t.co/EmXhJ5GFqD @AmJGastro

[Nilang Patel, MD, MS, FASN @nilangpatel]

Combination therapy reduced more proteinuria than either agent alone..

[Rajiv Agarwal MD, MS @AgarwalRajivMD]

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.

[VA Research @VAResearch]

CIPHER is excited to announce our partnership with #OHDSI! A core part of OMOP’s Common Data Model, OHDSI’s standardized vocabularies enable the harmonization of terminologies across clinical domains that allows for collaborative research and large-scale analytics. @OHDSI

[Nilang Patel, MD, MS, FASN @nilangpatel]

@proychaudhuryMD @DrDeidraCrews @ASNAdvocacy @UNCKidney Congratulations

[Nilang Patel, MD, MS, FASN @nilangpatel]

@UvaDOM @UVANeph @MarkOkusa Congratulations

[Jasmohan Bajaj @JasmohanBajaj]

🙏 for highlighting our @VAResearch & @TriNetX study!
@nilangpatel @DrJackieOleary @VCU_CCTR @MedPageID @HealioGastro @gardp_amr

[Jasmohan Bajaj @JasmohanBajaj]

🙏 @EASLnews for invite to present data on #machinelearning to exclude #SBP in @VAResearch @VCUresearch cohorts @EASLnews #EASLCongress. Great negative predictive value giving hope to those w limited resources. 🙏 @di_martinov for 📸 @nilangpatel @VCU_CCTR

[Nilang Patel, MD, MS, FASN @nilangpatel]

❓How much Hgb🩸increase would you expect if we give oral Iron tablet daily vs. 2-3 times/day vs. alternate day in #Irondeficiency #Anemia

🔑Hgb🩸⬆️ 1.03 g/dL in daily, ⬆️ 1.38 g/dL in >= 2 times/day and ⬆️ 0.93 g/dL in alternate day group at 90 days in patients normal kidney function.

🔑Hgb🩸⬆️ 0.71 g/dL in daily, 0.99 g/dL in in >= 2 times/day, and 0.62 g/dL in alternate day group at 90 days in patients with #CKD

Check out our recently published study @JAMANetworkOpen @JAMANetwork @ASH_hematology @aafp @EHA_Hematology @VAResearch @RichmondVAMC @JasmohanBajaj @Iron_Deficiency @IronResearchLab @BioIronSocial @VCU @VCUHealth @VCU_Nephrology @HematologyTweet @goKDIGO @ASNKidney #Nephtwitter

[JAMA Network Open @JAMANetworkOpen]

Cohort study signifies the importance of following the standard clinical practice (2-3 times a day oral iron supplementation) in iron deficiency anemia when a rapid rise of hemoglobin is desired. https://t.co/67wMqNu7sJ

[Nilang Patel, MD, MS, FASN @nilangpatel]

How often should we give #Oral #Iron supplements to patients with #Irondeficiency #anemia?

We studied > 70,000 patients with IDA. ⬆️ Hgb🩸is similar in daily and alternate-day groups but happened at a slower pace ⬇️compared to >= 2 times/day. This difference in dose response is important for general internists to be aware of when treating severe cases of IDA. @JAMANetwork @ASH_hematology @aafp @EHA_Hematology @VAResearch @RichmondVAMC @JasmohanBajaj @Iron_Deficiency @IronResearchLab @BioIronSocial @VCU @VCUHealth @HematologyTweet

[JAMA Network Open @JAMANetworkOpen]

Cohort study signifies the importance of following the standard clinical practice (2-3 times a day oral iron supplementation) in iron deficiency anemia when a rapid rise of hemoglobin is desired. https://t.co/67wMqNu7sJ

[Nilang Patel, MD, MS, FASN @nilangpatel]

#IronDeficiency #Anemia is widely prevalent(~ 10-20% globally). #Oral #Iron is the mainstay of treatment. But, how do you give this? > = 2 times/d, 1/d or alternate day? Would they have a similar response? Checkout our recently published study
https://t.co/qYSMCQWk6q

[Nilang Patel, MD, MS, FASN @nilangpatel]

Our work is being quoted @nytimes. We showed that 10% patients of #dementia could have reversible cause. #cirrhosis @RichmondVAMC @VAResearch

[Jasmohan Bajaj @JasmohanBajaj]

Our study is mentioned ⁦⁦@nytimes⁩ !!!What to Know About Mild Cognitive Impairment Treatment - The New York Times ⁦@JAMANetworkOpen⁩ https://t.co/Fqnanon97c. #cirrhosis #dementia ⁦@VAResearch⁩ ⁦@VCUresearch⁩ ⁦@nilangpatel⁩ https://t.co/2sB8lYIB72

[Jasmohan Bajaj @JasmohanBajaj]

Our study is mentioned ⁦⁦@nytimes⁩ !!!What to Know About Mild Cognitive Impairment Treatment - The New York Times ⁦@JAMANetworkOpen⁩ https://t.co/Fqnanon97c. #cirrhosis #dementia ⁦@VAResearch⁩ ⁦@VCUresearch⁩ ⁦@nilangpatel⁩ https://t.co/2sB8lYIB72

[Nilang Patel, MD, MS, FASN @nilangpatel]

@WUNephrology @anuja_java @womeninnephro @WUICTS @WUDeptMedicine Congratulations